| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/11/2009 | US20090148495 Optimum Density Fibrous Matrix |
| 06/11/2009 | US20090148494 Egfr inhibitors promote axon regeneration |
| 06/11/2009 | US20090148479 Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| 06/11/2009 | US20090148478 Combinations of tumor-associated antigens in compositions for various types of cancers |
| 06/11/2009 | US20090148477 Adenoviral vector-based malaria vaccines |
| 06/11/2009 | US20090148476 Chemodenervating pharmaceutical as anti-inflammatory agent |
| 06/11/2009 | US20090148475 Glycoprotein 5 (GP5) and M protein of PRRSV linked by a disulfide bond gives rise to protective antigenic determinant (PAD polypeptide) that is used provide protection PRRSV; immunizing pigs |
| 06/11/2009 | US20090148474 Determing virulence via replication and hybridization; immunogens |
| 06/11/2009 | US20090148473 Microbial vaccine and vaccine vector |
| 06/11/2009 | US20090148472 Identification of protective antigenic determinants of porcine reproductive and respiratory syndrome virus and uses thereof |
| 06/11/2009 | US20090148471 Molecular Vaccine Linking an Endoplasmic Reticulum Chaperone Polypeptide to an Antigen |
| 06/11/2009 | US20090148470 Protein-based streptococcus pneumoniae vaccines |
| 06/11/2009 | US20090148469 Multicomponent meningococcal vaccine |
| 06/11/2009 | US20090148468 Screening blood and identifying immunologically active antigen of herpes simplex virus (HSV) which attacks skin; diagnosing viral infection; viricides |
| 06/11/2009 | US20090148467 Herpes simplex virus combined subunit vaccines and methods of use thereof |
| 06/11/2009 | US20090148466 Process for the Preparation of Hypoallergenic Mosaic Antigens |
| 06/11/2009 | US20090148465 Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
| 06/11/2009 | US20090148464 Preventive or therapeutic agent containing anti thioredoxin antibody polypeptide as an active ingredient for disorders |
| 06/11/2009 | US20090148463 Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease |
| 06/11/2009 | US20090148462 Methods and compositions for use in treatment of patients with autoantibody positive disease |
| 06/11/2009 | US20090148461 Anti fgf23 antibody and a pharmaceutical composition comprising the same |
| 06/11/2009 | US20090148460 Exosome ligands, their preparation and uses |
| 06/11/2009 | US20090148459 Prevention or Treatment of Cancer Using Integrin alphavbeta3 Antagonists in Combination with Other Agents |
| 06/11/2009 | US20090148458 Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy |
| 06/11/2009 | US20090148457 Hepatocyte growth factor receptor antagonists and uses thereof |
| 06/11/2009 | US20090148456 Canine rankl and methods for preparing and using the same |
| 06/11/2009 | US20090148455 Anti-RANTES antibodies and methods of use thereof |
| 06/11/2009 | US20090148454 Peptide Domain Required For Interaction Between The Envelope of a Virus Pertaining to The Herv-W Interference Group and an Hasct Receptor |
| 06/11/2009 | US20090148453 Monoclonal antibodies against HMGB1 |
| 06/11/2009 | US20090148452 Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
| 06/11/2009 | US20090148451 Therapeutic anti-cytomegalovirus compounds |
| 06/11/2009 | US20090148450 ATF4 As A Therapeutic Target In Alzheimers Disease And Other Neurological Disorders |
| 06/11/2009 | US20090148449 Antibodies against cd38 for treatment of multiple myeloma |
| 06/11/2009 | US20090148448 Methods and compositions for modulating and detecting wisp activity |
| 06/11/2009 | US20090148447 Binding Peptides Having a C-terminally Disposed Specific Binding Domain |
| 06/11/2009 | US20090148446 Method and Composition for Treatment of Renal Failure with Antibodies and Their Equivalents as Partial or Complete Replacement for Dialysis |
| 06/11/2009 | US20090148445 Methods of sensitizing cancer to therapy-induced cytotoxicity |
| 06/11/2009 | US20090148444 Pharmaceutical composition for treating immune diseases |
| 06/11/2009 | US20090148443 Humanized antibodies and compositions for binding sphingosine-1-phosphate |
| 06/11/2009 | US20090148442 COMBINATION OF BLyS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE |
| 06/11/2009 | US20090148441 Anti-Cancer Antibodies With Reduced Complement Fixation |
| 06/11/2009 | US20090148440 Antibodies against interleukin-22 binding protein and its uses for the treatment of metabolic disorders |
| 06/11/2009 | US20090148439 by use of a polypeptide (CD27L); in particular kidney cancer; monitoring the effectiveness of epithelial-derived cancer therapy |
| 06/11/2009 | US20090148438 Binding Moieties Based on Shark Ignar Domains |
| 06/11/2009 | US20090148437 Polypeptides, antibody variable domains & antagonists |
| 06/11/2009 | US20090148436 Antibody to gdf8 and uses thereof |
| 06/11/2009 | US20090148435 Antibody purification by cation exchange chromatography |
| 06/11/2009 | US20090148434 Antibody Compositions and Methods |
| 06/11/2009 | US20090148407 Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication |
| 06/11/2009 | US20090148406 Stable Aqueous Systems Comprising Proteins |
| 06/11/2009 | US20090148405 Induction of dendritic cell development with macrophage-colony stimulating factor (m-csf) receptor ligands |
| 06/11/2009 | US20090148404 Compositions and methods for eliminating undesired subpopulations of t cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| 06/11/2009 | US20090148402 Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies |
| 06/11/2009 | US20090148400 Composition of tumour-associated peptides and related anti-cancer vaccine |
| 06/11/2009 | US20090148389 Induction of mucosal tolerance to antigens |
| 06/11/2009 | US20090148383 Anticoagulation Agent and Uses Thereof |
| 06/11/2009 | CA2744739A1 Chlamydia antigens |
| 06/11/2009 | CA2708532A1 Anti-nr10 antibody and use thereof |
| 06/11/2009 | CA2708251A1 Humanized antibody molecules specific for il-31 |
| 06/11/2009 | CA2708065A1 Therapeutic agent for pruritus |
| 06/11/2009 | CA2707919A1 A subunit vaccine for aquaculture |
| 06/11/2009 | CA2707689A1 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
| 06/11/2009 | CA2707483A1 Protein formulations and methods of making same |
| 06/11/2009 | CA2707247A1 Influenza composition |
| 06/11/2009 | CA2707245A1 Vaccine |
| 06/11/2009 | CA2707201A1 G immunoglobulin used against anthrax toxins |
| 06/11/2009 | CA2707013A1 Immunotherapeutic method for increasing groundnut tolerance in a subject |
| 06/11/2009 | CA2706907A1 Cancer vaccine composition |
| 06/11/2009 | CA2706337A1 Method of inhibition of leukemic stem cells |
| 06/11/2009 | CA2706258A1 Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof |
| 06/11/2009 | CA2706101A1 A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant |
| 06/11/2009 | CA2705461A1 Novel vaccines against multiple subtypes of influenza virus |
| 06/11/2009 | CA2703790A1 Anti-vegf antibodies |
| 06/10/2009 | EP2067863A2 Methods and compositions for diseases associated with amyloidosis |
| 06/10/2009 | EP2067862A1 Gridlock nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 06/10/2009 | EP2067792A2 Inhibitory antibodies of HER3 activity |
| 06/10/2009 | EP2067791A1 Prophylactic or therapeutic agent for cancer |
| 06/10/2009 | EP2067790A2 Agonist antibody against protein tyrosine kinase SAL-S1 |
| 06/10/2009 | EP2067789A1 Anti-P selectin antibodies |
| 06/10/2009 | EP2067783A1 Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof |
| 06/10/2009 | EP2067488A1 Albumin fusion proteins |
| 06/10/2009 | EP2067487A2 Immunomodulatory formulations and methods for use thereof |
| 06/10/2009 | EP2067486A1 Use of CD23 antagonists for the treatment of neoplastic disorders |
| 06/10/2009 | EP2067480A1 Musclin receptor and use thereof |
| 06/10/2009 | EP2067472A1 Compositions and methods for the diagnosis and treatment of tumor |
| 06/10/2009 | EP2066696A1 Anti-cancer antibodies against lewisy and lewisb antigens |
| 06/10/2009 | EP2066694A2 Compositions and methods for diagnosing and treating cancer |
| 06/10/2009 | EP2066354A1 Norovirus vaccine formulations |
| 06/10/2009 | EP2066353A1 Combination of zd6474 and bevacizumab for cancer therapy |
| 06/10/2009 | EP2066352A1 Treatment of multiple sclerosis (ms) with campath-1h |
| 06/10/2009 | EP2066351A2 Human antibodies that bind cxcr4 and uses thereof |
| 06/10/2009 | EP2066350A2 Stabilized antibody formulations and uses thereof |
| 06/10/2009 | EP2066349A2 Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 06/10/2009 | EP2066348A1 Compositions and methods for enhancing an adjuvant |
| 06/10/2009 | EP2066347A1 Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases |
| 06/10/2009 | EP2066346A2 Alphavirus replicon particles encoding il-12 as immunological adjuvants |
| 06/10/2009 | EP2066345A2 Making influenza virus vaccines without using eggs |
| 06/10/2009 | EP2066344A1 Vaccine |
| 06/10/2009 | EP2066343A2 Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications |
| 06/10/2009 | EP2066341A1 Method of eliciting or inducing an immune response |